SLC25A39

Across TCGA pan-cancer cohorts, SLC25A39 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SLC25A39’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SLC25A39 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC25A39 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

BLCA, COAD, and HNSC are the cancer types where SLC25A39 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A39 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+1.342	<.001	11	view →
COAD	Female	II,III,IV	+1.045	<.001	11	view →
HNSC	Male	All	+0.917	<.001	11	view →
LIHC	Female	II,III,IV	+1.476	<.001	9	view →
LUAD	Male	III,IV	+1.405	<.001	9	view →
STAD	All	All	+1.049	<.001	9	view →
KIRC	Male	II,III,IV	−0.769	<.001	9	view →
LUSC	Female	II,III,IV	+1.595	<.001	8	view →
KICH	All	All	+0.511	.001	8	view →
UCEC	All	III,IV	+1.593	<.001	6	view →
BRCA	All	III,IV	+1.086	<.001	6	view →
CHOL	Female	All	+2.293	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SLC25A39–BLCA

Open the BLCA breakdown →